Giant Axonal Neuropathy (GAN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Giant Axonal Neuropathy (GAN) is a rare autosomal recessive neurodegenerative disorder impacting both the central and peripheral nervous systems, typically characterized by progressive weakness and ataxia. Alongside these symptoms, individuals experience sensory loss and eventual loss of ambulation, often leading to respiratory failure. The condition stems from an anomaly within the GAN gene, found on chromosome 16 at 16q24.1, responsible for encoding the gigaxonin protein. This abnormal protein results in the swelling of axons, where tiny thread-like deposits of neurofilaments accumulate, creating the appearance of giant axons. Consequently, this leads to degeneration and dysfunctional activity within the peripheral nervous system. Neuropathological investigations have revealed a loss of gigaxonin expression affecting regions such as the cerebellar cortex, brainstem, and posterior columns of the spinal cord. Consequently, this disorder is considered a promising candidate for intrathecal delivery of AAV9 gene transfer, aiming to restore gigaxonin function. Gigaxonin plays a crucial role in organizing and degrading intermediate filaments. Thus, its absence leads to axonal enlargement characterized by densely bundled intermediate filaments. Standard features of Giant Axonal Neuropathy include hypotonia (low muscle tone), muscle weakness, diminished reflexes, ataxia, seizures, and intellectual disability. Regrettably, there are currently no FDA-approved treatments for GAN. Management primarily revolves around counseling and symptomatic approaches, including bracing, physical therapy, aquatic therapy, and pain management.

·       In the United States, the prevalence of Giant Axonal Neuropathy ranges from 0.4 to 0.78 cases per million population.

 

Thelansis’s “Giant Axonal Neuropathy (GAN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Giant Axonal Neuropathy (GAN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Giant Axonal Neuropathy (GAN) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Giant Axonal Neuropathy (GAN) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Giant Axonal Neuropathy (GAN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Giant Axonal Neuropathy (GAN), Giant Axonal Neuropathy (GAN) market outlook, Giant Axonal Neuropathy (GAN) competitive landscape, Giant Axonal Neuropathy (GAN) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)